The DOI matches its Crossref record; 485 of the 485 references it cites were found in a registry or an index.
Classification of current anticancer immunotherapies
Open accessAbstract
// Lorenzo Galluzzi 1,2,3,4,* , Erika Vacchelli 1,2,3 , José-Manuel Bravo-San Pedro 1,2,3 , Aitziber Buqué 1,2,3 , Laura Senovilla 1,2,3 , Elisa Elena Baracco 1,2,3,5 , Norma Bloy 1,2,3,5 , Francesca Castoldi 1,2,3,5,6 , Jean-Pierre Abastado 7 , Patrizia Agostinis 8 , Ron N. Apte 9 , Fernando Aranda 1,2,3,10 , Maha Ayyoub 11,12 , Philipp Beckhove 13 , Jean-Yves Blay 14,15 , Laura Bracci 16 , Anne Caignard 17,18 , Chiara Castelli 19 , Federica Cavallo 20 , Estaban Celis 21 , Vincenzo Cerundolo 22 , Aled Clayton 23,24 , Mario P. Colombo 19 , Lisa Coussens 25 , Madhav V. Dhodapkar 26 , Alexander M. Eggermont 3 , Douglas T. Fearon 27 , Wolf H. Fridman 2,4,28,29 , Jitka Fučíková 6,30 , Dmitry I. Gabrilovich 31 , Jérôme Galon 2,4,28,32 , Abhishek Garg 8 , François Ghiringhelli 33,34,35 , Giuseppe Giaccone 36,37 , Eli Gilboa 38 , Sacha Gnjatic 39 , Axel Hoos 40 , Anne Hosmalin 4,41,42,43 , Dirk Jäger 44 , Pawel Kalinski 45,46,47 , Klas Kärre 48 , Oliver Kepp 1,2,49 , Rolf Kiessling 50 , John M. Kirkwood 51 , Eva Klein 48 , Alexander Knuth 52 , Claire E. Lewis 53 , Roland Liblau 54,55,56 , Michael T. Lotze 45,46 , Enrico Lugli 57 , Jean-Pierre Mach 58 , Fabrizio Mattei 16 , Domenico Mavilio 57,59 , Ignacio Melero 60,61 , Cornelis J. Melief 62,63 , Elizabeth A. Mittendorf 64 , Lorenzo Moretta 65 , Adekunke Odunsi 66 , Hideho Okada 67 , Anna Karolina Palucka 68 , Marcus E. Peter 69 , Kenneth J. Pienta 70 , Angel Porgador 9 , George C. Prendergast 71,72,73 , Gabriel A. Rabinovich 74 , Nicholas P. Restifo 75 , Naiyer Rizvi 76 , Catherine Sautès-Fridman 2,4,28,29 , Hans Schreiber 77 , Barbara Seliger 78 , Hiroshi Shiku 79 , Bruno Silva-Santos 80 , Mark J. Smyth 81,82 , Daniel E. Speiser 83,84 , Radek Spisek 6,30 , Pramod K. Srivastava 85,86 , James E. Talmadge 87 , Eric Tartour 4,88,89,90 , Sjoerd H. Van Der Burg 91 , Benoît J. Van Den Eynde 92,93,94 , Richard Vile 95 , Hermann Wagner 96 , Jeffrey S. Weber 97 , Theresa L. Whiteside 46,98 , Jedd D. Wolchok 99,100 , Laurence Zitvogel 3,101,102 , Weiping Zou 103 and Guido Kroemer 1,2,4,49,104,* 1 Equipe 11 labellisée pas la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, Paris, France 2 INSERM, U1138, Paris, France 3 Gustave Roussy Cancer Campus, Villejuif, France 4 Université Paris Descartes/Paris V, Sorbonne Paris Cité, Paris, France 5 Faculté de Medicine, Université Paris Sud/Paris XI, Le Kremlin-Bicêtre, France 6 Sotio a.c., Prague, Czech Republic 7 Pole d’innovation thérapeutique en oncologie, Institut de Recherches Internationales Servier, Suresnes, France 8 Cell Death Research and Therapy (CDRT) Laboratory, Dept. of Cellular and Molecular Medicine, University of Leuven, Leuven, Belgium 9 The Shraga Segal Dept. of Microbiology, Immunology and Genetics, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel 10 Group of Immune receptors of the Innate and Adaptive System, Institut d’Investigacions Biomédiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain 11 INSERM, U1102, Saint Herblain, France 12 Institut de Cancérologie de l’Ouest, Saint Herblain, France 13 Translational Immunology Division, German Cancer Research Center, Heidelberg, Germany 14 Equipe 11, Centre Léon Bérard (CLR), Lyon, France 15 Centre de Recherche en Cancérologie de Lyon (CRCL), Lyon, France 16 Dept. of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy 17 INSERM, U1160, Paris, France 18 Groupe Hospitalier Saint Louis-Lariboisière - F. Vidal, Paris, France 19 Unit of Immunotherapy of Human Tumors, Dept. of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy 20 Molecular Biotechnology Center, Dept. of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy 21 Cancer Immunology, Inflammation and Tolerance Program, Georgia Regents University Cancer Center, Augusta, GA, USA 22 MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK 23 Institute of Cancer & Genetics, School of Medicine, Cardiff University, Cardiff, UK 24 Velindre Cancer Centre, Cardiff, UK 25 Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA 26 Sect. of Hematology and Immunobiology, Yale Cancer Center, Yale University, New Haven, CT, USA 27 Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA 28 Université Pierre et Marie Curie/Paris VI, Paris, France 29 Equipe 13, Centre de Recherche des Cordeliers, Paris, France 30 Dept. of Immunology, 2nd Faculty of Medicine and University Hospital Motol, Charles University, Prague, Czech Republic 31 Dept. of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA 32 Laboratory of Integrative Cancer Immunology, Centre de Recherche des Cordeliers, Paris, France 33 INSERM, UMR866, Dijon, France 34 Centre Georges François Leclerc, Dijon, France 35 Université de Bourgogne, Dijon, France 36 Center for Cance
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Items 201–400 of 485
Zhou, J., Shen, X., Huang, J., Hodes, R. J., Rosenberg, S. A., & Robbins, P. F. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.10.7046 · Cited by 335
Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40
Sugamura, K., Ishii, N., & Weinberg, A. D. (2004) · Nature Reviews Immunology · doi:10.1038/nri1371 · Cited by 335
Oncolytic viruses in cancer therapy
Vähä-Koskela, M. J. V., Heikkilä, J. E., & Hinkkanen, A. E. (2007) · Cancer Letters · doi:10.1016/j.canlet.2007.02.002 · Cited by 333
Wood, C., Srivastava, P., Bukowski, R., Lacombe, L., Gorelov, A. I., Gorelov, S., Mulders, P., Zielinski, H., Hoos, A., Teofilovici, F., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60697-2 · Cited by 332
Self-citationDendritic Cell-Derived Exosomes for Cancer Immunotherapy: What's Next?
Viaud, S., Théry, C., Ploix, S., Tursz, T., Lapierre, V., Lantz, O., Zitvogel, L., & Chaput, N. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3276 · Cited by 332
Self-citationDesigning Vaccines Based on Biology of Human Dendritic Cell Subsets
Palucka, K., Banchereau, J., & Mellman, I. (2010) · Immunity · doi:10.1016/j.immuni.2010.10.007 · Cited by 332
Burger, J. A., Keating, M. J., Wierda, W. G., Hartmann, E., Hoellenriegel, J., Rosin, N. Y., de Weerdt, I., Jeyakumar, G., Ferrajoli, A., Cardenas-Turanzas, M., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70335-3 · Cited by 332
Bergman, P. J., McKnight, J. A., Novosad, A., Charney, S. C., Farrelly, J., Craft, D. M., Wulderk, M., Jeffers, Y., Sadelain, M., Hohenhaus, A. E., et al. (2003) · PubMed · Cited by 330
Self-citationB regulatory cells and the tumor-promoting actions of TNF-α during squamous carcinogenesis
Schioppa, T., Moore, R., Thompson, R. G., Rosser, E. C., Kulbe, H., Nedospasov, S., Mauri, C., Coussens, L. M., & Balkwill, F. R. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1100994108 · Cited by 328
Self-citationTrial watch: IDO inhibitors in cancer therapy
Vacchelli, E., Aranda, F., Eggermont, A., Sautès-Fridman, C., Tartour, E., Kennedy, E. P., Platten, M., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2014) · OncoImmunology · doi:10.4161/21624011.2014.957994 · Cited by 326
Self-citationIDO Is a Nodal Pathogenic Driver of Lung Cancer and Metastasis Development
Smith, C., Chang, M. Y., Parker, K. H., Beury, D. W., DuHadaway, J. B., Flick, H. E., Boulden, J., Sutanto-Ward, E., Soler, A. P., Laury-Kleintop, L. D., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0014 · Cited by 322
Self-citationSrivastava, R. M., Lee, S. C., Andrade Filho, P. A., Lord, C. A., Jie, H.-B., Davidson, H. C., López-Albaitero, A., Gibson, S. P., Gooding, W. E., Ferrone, S., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2426 · Cited by 318
Iclozan, C., Antonia, S., Chiappori, A., Chen, D.-T., & Gabrilovich, D. (2013) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-013-1396-8 · Cited by 317
Self-citationPolymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies
Fisher, K., Stallwood, Y., Green, N., Ulbrich, K., Mautner, V, & Seymour, L. (2001) · Gene Therapy · doi:10.1038/sj.gt.3301389 · Cited by 316
Beatty, G. L., O'Dwyer, P. J., Clark, J., Shi, J. G., Bowman, K. J., Scherle, P. A., Newton, R. C., Schaub, R., Maleski, J., Leopold, L., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2272 · Cited by 314
Boczkowski, D., Nair, S. K., Nam, J., Lyerly, H. K., & Gilboa, E. (2000) · PubMed · Cited by 313
Self-citationCell transfer immunotherapy for metastatic solid cancer—what clinicians need to know
Rosenberg, S. A. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.116 · Cited by 312
Targeting Cancer-Derived Adenosine:New Therapeutic Approaches
Young, A., Mittal, D., Stagg, J., & Smyth, M. J. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0341 · Cited by 310
Self-citationHinrichs, C. S., Borman, Z. A., Gattinoni, L., Yu, Z., Burns, W. R., Huang, J., Klebanoff, C. A., Johnson, L. A., Kerkar, S. P., Yang, S., et al. (2011) · Blood · doi:10.1182/blood-2010-05-286286 · Cited by 307
Self-citationCancer prevention by targeting angiogenesis
Albini, A., Tosetti, F., Li, V. W., Noonan, D. M., & Li, W. W. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.120 · Cited by 306
B Cells Regulate Macrophage Phenotype and Response to Chemotherapy in Squamous Carcinomas
Affara, N. I., Ruffell, B., Medler, T. R., Gunderson, A. J., Johansson, M., Bornstein, S., Bergsland, E., Steinhoff, M., Li, Y., Gong, Q., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.04.026 · Cited by 304
Self-citationUnleashing the potential of NOD- and Toll-like agonists as vaccine adjuvants
Maisonneuve, C., Bertholet, S., Philpott, D. J., & De Gregorio, E. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1400478111 · Cited by 303
Morse, M. A., Hobeika, A. C., Osada, T., Serra, D., Niedzwiecki, D., Lyerly, H. K., & Clay, T. M. (2008) · Blood · doi:10.1182/blood-2008-01-135319 · Cited by 300
Jenq, R. R., & van den Brink, M. R. M. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2804 · Cited by 299
Valmori, D., Souleimanian, N. E., Tosello, V., Bhardwaj, N., Adams, S., O'Neill, D., Pavlick, A., Escalon, J. B., Cruz, C. M., Angiulli, A., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0703395104 · Cited by 299
Self-citationPD-L1 blockade synergizes with IL-2 therapy in reinvigorating exhausted T cells
West, E. E., Jin, H.-T., Rasheed, A.-U., Penaloza-MacMaster, P., Ha, S.-J., Tan, W. G., Youngblood, B., Freeman, G. J., Smith, K. A., & Ahmed, R. (2013) · Journal of Clinical Investigation · doi:10.1172/jci67008 · Cited by 298
Wang, M., Fayad, L., Wagner-Bartak, N., Zhang, L., Hagemeister, F., Neelapu, S. S., Samaniego, F., McLaughlin, P., Fanale, M., Younes, A., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70200-0 · Cited by 297
Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy
Kepp, O., Galluzzi, L., Martins, I., Schlemmer, F., Adjemian, S., Michaud, M., Sukkurwala, A. Q., Menger, L., Zitvogel, L., & Kroemer, G. (2011) · Cancer and Metastasis Reviews · doi:10.1007/s10555-011-9273-4 · Cited by 297
Self-citationGarg, A. D., Krysko, D. V., Vandenabeele, P., & Agostinis, P. (2012) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-011-1184-2 · Cited by 292
Self-citationAttia, P., Maker, A. V., Haworth, L. R., Rogers-Freezer, L., & Rosenberg, S. A. (2005) · Journal of Immunotherapy · doi:10.1097/01.cji.0000175468.19742.10 · Cited by 286
The GITR–GITRL interaction: co-stimulation or contrasuppression of regulatory activity?
Shevach, E. M., & Stephens, G. L. (2006) · Nature Reviews Immunology · doi:10.1038/nri1867 · Cited by 281
Bijker, M. S., van den Eeden, S. J. F., Franken, K. L., Melief, C. J. M., Offringa, R., & van der Burg, S. H. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.8.5033 · Cited by 279
Self-citationIliopoulou, E. G., Kountourakis, P., Karamouzis, M. V., Doufexis, D., Ardavanis, A., Baxevanis, C. N., Rigatos, G., Papamichail, M., & Perez, S. A. (2010) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-010-0904-3 · Cited by 277
Extracellular ATP drives systemic inflammation, tissue damage and mortality
Cauwels, A., Rogge, E., Vandendriessche, B., Shiva, S., & Brouckaert, P. (2014) · Cell Death & Disease · doi:10.1038/cddis.2014.70 · Cited by 274
STAT3-Driven Upregulation of TLR2 Promotes Gastric Tumorigenesis Independent of Tumor Inflammation
Tye, H., Kennedy, C. L., Najdovska, M., McLeod, L., McCormack, W., Hughes, N., Dev, A., Sievert, W., Ooi, C. H., Ishikawa, T.-O., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.08.010 · Cited by 273
Tacken, P. J., de Vries, I. J. M., Gijzen, K., Joosten, B., Wu, D., Rother, R. P., Faas, S. J., Punt, C. J. A., Torensma, R., Adema, G. J., et al. (2005) · Blood · doi:10.1182/blood-2005-01-0318 · Cited by 272
A Modified Polyriboinosinic-Polyribocytidylic Acid Complex That Induces Interferon in Primates
Levy, H. B., Baer, G., Baron, S., Buckler, C. E., Gibbs, C. J., Iadarola, M. J., London, W. T., & Rice, J. (1975) · Journal of Infectious Diseases · doi:10.1093/infdis/132.4.434 · Cited by 270
Plasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance?
Hölzel, M., Bovier, A., & Tüting, T. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3498 · Cited by 269
Adoptive Immunotherapy for Cancer or Viruses
Maus, M. V., Fraietta, J. A., Levine, B. L., Kalos, M., Zhao, Y., & June, C. H. (2014) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032713-120136 · Cited by 264
Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors
Muller, A. J., & Scherle, P. A. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1929 · Cited by 262
Molecular mechanisms of regulated necrosis
Galluzzi, L., Kepp, O., Krautwald, S., Kroemer, G., & Linkermann, A. (2014) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2014.02.006 · Cited by 258
Self-citationTargeting Dendritic Cells with Antigen-Containing Liposomes
van Broekhoven, C. L., Parish, C. R., Demangel, C., Britton, W. J., & Altin, J. G. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0138 · Cited by 256
Trial watch: Oncolytic viruses for cancer therapy
Vacchelli, E., Eggermont, A., Sautès-Fridman, C., Galon, J., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2013) · OncoImmunology · doi:10.4161/onci.24612 · Cited by 255
Self-citationSchreibelt, G., Klinkenberg, L. J. J., Cruz, L. J., Tacken, P. J., Tel, J., Kreutz, M., Adema, G. J., Brown, G. D., Figdor, C. G., & de Vries, I. J. M. (2012) · Blood · doi:10.1182/blood-2011-08-373944 · Cited by 252
Trial watch: Dendritic cell-based interventions for cancer therapy
Vacchelli, E., Vitale, I., Eggermont, A., Fridman, W. H., Fučíková, J., Cremer, I., Galon, J., Tartour, E., Zitvogel, L., Kroemer, G., et al. (2013) · OncoImmunology · doi:10.4161/onci.25771 · Cited by 247
Self-citationTrial watch: FDA-approved Toll-like receptor agonists for cancer therapy
Vacchelli, E., Galluzzi, L., Eggermont, A., Fridman, W. H., Galon, J., Sautès-Fridman, C., Tartour, E., Zitvogel, L., & Kroemer, G. (2012) · OncoImmunology · doi:10.4161/onci.20931 · Cited by 244
Self-citationMuller, A. J., Sharma, M. D., Chandler, P. R., DuHadaway, J. B., Everhart, M. E., Johnson, B. A., Kahler, D. J., Pihkala, J., Soler, A. P., Munn, D. H., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806173105 · Cited by 240
Self-citationOrganelle-specific initiation of cell death
Galluzzi, L., Bravo-San Pedro, J. M., & Kroemer, G. (2014) · Nature Cell Biology · doi:10.1038/ncb3005 · Cited by 239
Self-citationWang, J., Saffold, S., Cao, X., Krauss, J., & Chen, W. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.10.5516 · Cited by 237
Cherfils-Vicini, J., Platonova, S., Gillard, M., Laurans, L., Validire, P., Caliandro, R., Magdeleinat, P., Mami-Chouaib, F., Dieu-Nosjean, M.-C., Fridman, W.-H., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci36551 · Cited by 237
Self-citationTrial watch: Prognostic and predictive value of the immune infiltrate in cancer
Senovilla, L., Vacchelli, E., Galon, J., Adjemian, S., Eggermont, A., Fridman, W. H., Sautès-Fridman, C., Ma, Y., Tartour, E., Zitvogel, L., et al. (2012) · OncoImmunology · doi:10.4161/onci.22009 · Cited by 235
Self-citationStudies on the Anticancer and Streptolysin S‐Forming Abilities of Hemolytic Streptococci
Okamoto, H., Shoin, S., Koshimura, S., & Shimizu, R. (1967) · Japanese Journal of Microbiology · doi:10.1111/j.1348-0421.1967.tb00350.x · Cited by 232
Raje, N., & Anderson, K. (1999) · New England Journal of Medicine · doi:10.1056/nejm199911183412110 · Cited by 230
IL-2 therapy promotes suppressive ICOS+ Treg expansion in melanoma patients
Sim, G. C., Martin-Orozco, N., Jin, L., Yang, Y., Wu, S., Washington, E., Sanders, D., Lacey, C., Wang, Y., Vence, L., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci46266 · Cited by 229
Nishioka, Y., Hirao, M., Robbins, P. D., Lotze, M. T., & Tahara, H. (1999) · PubMed · Cited by 228
Self-citationDanger signalling during cancer cell death: origins, plasticity and regulation
Garg, A. D., Martin, S., Golab, J., & Agostinis, P. (2014) · Cell Death & Differentiation · doi:10.1038/cdd.2013.48 · Cited by 226
Self-citationSuzuki, Y., Mimura, K., Yoshimoto, Y., Watanabe, M., Ohkubo, Y., Izawa, S., Murata, K., Fujii, H., Nakano, T., & Kono, K. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0851 · Cited by 219
Cross-priming CD8+ T cells by targeting antigens to human dendritic cells through DCIR
Klechevsky, E., Flamar, A.-L., Cao, Y., Blanck, J.-P., Liu, M., O'Bar, A., Agouna-Deciat, O., Klucar, P., Thompson-Snipes, L., Zurawski, S., et al. (2010) · Blood · doi:10.1182/blood-2010-01-264960 · Cited by 214
Self-citationKuhne, M. R., Mulvey, T., Belanger, B., Chen, S., Pan, C., Chong, C., Cao, F., Niekro, W., Kempe, T., Henning, K. A., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2333 · Cited by 211
Fallarino, F., Asselin-Paturel, C., Vacca, C., Bianchi, R., Gizzi, S., Fioretti, M. C., Trinchieri, G., Grohmann, U., & Puccetti, P. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.6.3748 · Cited by 211
Engineered lentivector targeting of dendritic cells for in vivo immunization
Yang, L., Yang, H., Rideout, K., Cho, T., Joo, K. I., Ziegler, L., Elliot, A., Walls, A., Yu, D., Baltimore, D., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1390 · Cited by 209
Ko, A., Kanehisa, A., Martins, I., Senovilla, L., Chargari, C., Dugue, D., Mariño, G., Kepp, O., Michaud, M., Perfettini, J.-L., et al. (2014) · Cell Death & Differentiation · doi:10.1038/cdd.2013.124 · Cited by 205
Self-citationENTPD1/CD39 is a promising therapeutic target in oncology
Bastid, J., Cottalorda-Regairaz, A., Alberici, G., Bonnefoy, N., Eliaou, J.-F., & Bensussan, A. (2013) · Oncogene · doi:10.1038/onc.2012.269 · Cited by 202
DNA Vaccines: Developing New Strategies against Cancer
Fioretti, D., Iurescia, S., Fazio, V. M., & Rinaldi, M. (2010) · Journal of Biomedicine and Biotechnology · doi:10.1155/2010/174378 · Cited by 202
Hombach, A. A., Heiders, J., Foppe, M., Chmielewski, M., & Abken, H. (2012) · OncoImmunology · doi:10.4161/onci.19855 · Cited by 200
Singh, H., Figliola, M. J., Dawson, M. J., Huls, H., Olivares, S., Switzer, K., Mi, T., Maiti, S., Kebriaei, P., Lee, D. A., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3843 · Cited by 199
Trial Watch: Experimental Toll-like receptor agonists for cancer therapy
Galluzzi, L., Vacchelli, E., Eggermont, A., Fridman, W. H., Galon, J., Sautès-Fridman, C., Tartour, E., Zitvogel, L., & Kroemer, G. (2012) · OncoImmunology · doi:10.4161/onci.20696 · Cited by 195
Self-citationBoissel, L., Betancur, M., Lu, W., Krause, D., Van Etten, R., Wels, W., & Klingemann, H. (2013) · OncoImmunology · doi:10.4161/onci.26527 · Cited by 194
Metz, R., Smith, C., DuHadaway, J. B., Chandler, P., Baban, B., Merlo, L. M. F., Pigott, E., Keough, M. P., Rust, S., Mellor, A. L., et al. (2014) · International Immunology · doi:10.1093/intimm/dxt073 · Cited by 190
Self-citationAntibody–drug conjugates for cancer: poised to deliver?
Hughes, B. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3270 · Cited by 188
Pembrolizumab: First Global Approval
Poole, R. M. (2014) · Drugs · doi:10.1007/s40265-014-0314-5 · Cited by 184
Yoshida, R., & Hayaishi, O. (1978) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.75.8.3998 · Cited by 181
Hayashi, T., Mo, J.-H., Gong, X., Rossetto, C., Jang, A., Beck, L., Elliott, G. I., Kufareva, I., Abagyan, R., Broide, D. H., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709261104 · Cited by 179
Celluzzi, C. M., & Falo, L. D. (1998) · PubMed · Cited by 178
Wildner, O., Blaese, R. M., & Morris, J. C. (1999) · PubMed · Cited by 177
Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus
Kanerva, A., Nokisalmi, P., Diaconu, I., Koski, A., Cerullo, V., Liikanen, I., Tähtinen, S., Oksanen, M., Heiskanen, R., Pesonen, S., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2546 · Cited by 177
Agonist Antibodies to TNFR Molecules That Costimulate T and NK Cells
Melero, I., Hirschhorn-Cymerman, D., Morales-Kastresana, A., Sanmamed, M. F., & Wolchok, J. D. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2065 · Cited by 176
Self-citationKawaguchi, Y., Kono, K., Mimura, K., Sugai, H., Akaike, H., & Fujii, H. (2007) · International Journal of Cancer · doi:10.1002/ijc.22370 · Cited by 174
Autophagy and pattern recognition receptors in innate immunity
Delgado, M., Singh, S., De Haro, S., Master, S., Ponpuak, M., Dinkins, C., Ornatowski, W., Vergne, I., & Deretic, V. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00725.x · Cited by 174
Maraba Virus as a Potent Oncolytic Vaccine Vector
Pol, J. G., Zhang, L., Bridle, B. W., Stephenson, K. B., Rességuier, J., Hanson, S., Chen, L., Kazdhan, N., Bramson, J. L., Stojdl, D. F., et al. (2014) · Molecular Therapy · doi:10.1038/mt.2013.249 · Cited by 173
Targeted delivery of TLR ligands to human and mouse dendritic cells strongly enhances adjuvanticity
Tacken, P. J., Zeelenberg, I. S., Cruz, L. J., van Hout-Kuijer, M. A., van de Glind, G., Fokkink, R. G., Lambeck, A. J. A., & Figdor, C. G. (2011) · Blood · doi:10.1182/blood-2011-07-367615 · Cited by 173
Trial watch: Peptide vaccines in cancer therapy
Vacchelli, E., Martins, I., Eggermont, A., Fridman, W. H., Galon, J., Sautès-Fridman, C., Tartour, E., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2012) · OncoImmunology · doi:10.4161/onci.22428 · Cited by 171
Self-citationClinical Development of Immunostimulatory Monoclonal Antibodies and Opportunities for Combination
Melero, I., Grimaldi, A. M., Perez-Gracia, J. L., & Ascierto, P. A. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2214 · Cited by 170
Self-citationDiaconu, I., Cerullo, V., Hirvinen, M. L. M., Escutenaire, S., Ugolini, M., Pesonen, S. K., Bramante, S., Parviainen, S., Kanerva, A., Loskog, A. S. I., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2975 · Cited by 162
Trial Watch: Toll-like receptor agonists for cancer therapy
Vacchelli, E., Eggermont, A. M. M., Sautès‐Fridman, C., Galon, J., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2013) · OncoImmunology · doi:10.4161/onci.25238 · Cited by 161
Self-citationCheung, N. V., Guo, H.-F., Hu, J., Tassev, D. V., & Cheung, I. Y. (2012) · OncoImmunology · doi:10.4161/onci.19864 · Cited by 159
Kandalaft, L. E., Powell, Jr., Chiang, C. L., Tanyi, J., Kim, S., Bosch, M., Montone, K., Mick, R., Levine, B. L., Torigian, D. A., et al. (2013) · OncoImmunology · doi:10.4161/onci.22664 · Cited by 159
Muller, G. W., Corral, L. G., Shire, M. G., Wang, H., Moreira, A., Kaplan, G., & Stirling, D. I. (1996) · Journal of Medicinal Chemistry · doi:10.1021/jm9603328 · Cited by 158
Designing and building the next generation of improved vaccine adjuvants
Brito, L. A., & O'Hagan, D. T. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.06.027 · Cited by 158
Adoptive Transfer of Tumor Reactive B Cells Confers Host T-Cell Immunity and Tumor Regression
Li, Q., Lao, X., Pan, Q., Ning, N., Yet, J., Xu, Y., Li, S., & Chang, A. E. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0207 · Cited by 158
Sondak, V. K., Smalley, K. S. M., Kudchadkar, R. R., Grippon, S., & Kirkpatrick, P. N. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3463 · Cited by 158
Trial watch: Dendritic cell-based interventions for cancer therapy
Galluzzi, L., Senovilla, L., Vacchelli, E., Eggermont, A. M. M., Fridman, W. H., Galon, J., Sautès‐Fridman, C., Tartour, É., Zitvogel, L., & Kroemer, G. (2012) · OncoImmunology · doi:10.4161/onci.21494 · Cited by 156
Self-citationDesign and development of synthetic peptide vaccines: past, present and future
Bijker, M. S., Melief, C. J. M., Offringa, R., & van der Burg, S. H. (2007) · Expert Review of Vaccines · doi:10.1586/14760584.6.4.591 · Cited by 155
Self-citationIkeda, K., Wakimoto, H., Ichikawa, T., et al. (2000) · Journal of Virology · doi:10.1128/jvi.74.10.4765-4775.2000 · Cited by 154
Trial Watch: Monoclonal antibodies in cancer therapy
Galluzzi, L., Vacchelli, E., Fridman, W. H., Galon, J., Sautès‐Fridman, C., Tartour, É., Zucman‐Rossi, J., Zitvogel, L., & Kroemer, G. (2012) · OncoImmunology · doi:10.4161/onci.1.1.17938 · Cited by 152
Self-citationSupernatural T cells: genetic modification of T cells for cancer therapy
Kershaw, M. H., Teng, M. W. L., Smyth, M. J., & Darcy, P. K. (2005) · Nature reviews. Immunology · doi:10.1038/nri1729 · Cited by 150
Self-citationMifamurtide for the treatment of nonmetastatic osteosarcoma
Ando, K., Mori, K., Corradini, N., Rédiní, F., & Heymann, D. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.543129 · Cited by 150
Higano, C. S., Small, E. J., Schellhammer, P. F., Yasothan, U., Gubernick, S. I., Kirkpatrick, P. N., & Kantoff, P. W. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3220 · Cited by 147
B cell-regulated immune responses in tumor models and cancer patients
Fremd, C., Schütz, F., Sohn, C., Beckhove, P., & Domschke, C. (2013) · OncoImmunology · doi:10.4161/onci.25443 · Cited by 143
Self-citationJoncker, N. T., & Raulet, D. H. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00658.x · Cited by 142
Enlightening the impact of immunogenic cell death in photodynamic cancer therapy
Galluzzi, L., Kepp, O., & Kroemer, G. (2012) · The EMBO Journal · doi:10.1038/emboj.2012.2 · Cited by 142
Self-citationCelluzzi, C. M., & Falo, L. D. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.160.7.3081 · Cited by 142
de La Motte Rouge, T., Galluzzi, L., Olaussen, K. A., Zermati, Y., Tasdemir, E., Robert, T., Ripoche, H., Lazar, V., Dessen, P., Harper, F., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0538 · Cited by 141
Self-citationPesonen, S. A., Diaconu, I., Kangasniemi, L., Ranki, T., Kanerva, A., Pesonen, S. K., Gerdemann, U., Leen, A. M., Kairemo, K., Oksanen, M., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3001 · Cited by 140
Immunogenic cell death in radiation therapy
Galluzzi, L., Kepp, O., & Kroemer, G. (2013) · OncoImmunology · doi:10.4161/onci.26536 · Cited by 138
Self-citationTumor-infiltrating lymphocytes, breast cancer subtypes and therapeutic efficacy
Loi, S. (2013) · OncoImmunology · doi:10.4161/onci.24720 · Cited by 134
Haicheur, N., Bismuth, E., Bosset, S., Adotévi, O., Warnier, G., Lacabanne, V., Régnault, A., Desaymard, C., Amigorena, S., Ricciardi‐Castagnoli, P., et al. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.6.3301 · Cited by 131
Self-citationBugaut, H., Bruchard, M., Berger, H., Dérangère, V., Odoul, L., Euvrard, R., Ladoire, S., Chalmin, F., Végran, F., Rébé, C., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0065181 · Cited by 130
Self-citationIversen, T. Z., Engell-Noerregaard, L., Ellebæk, E., Andersen, R. S., Larsen, S. K., Bjoern, J., Zeyher, C., Gouttefangeas, C., Thomsen, B. M., Holm, B., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1560 · Cited by 129
Dose and Schedule Study of Panitumumab Monotherapy in Patients with Advanced Solid Malignancies
Weiner, L. M., Belldegrun, A. S., Crawford, J., Tolcher, A. W., Lockbaum, P., Arends, R., Navale, L., Amado, R. G., Schwab, G. M., & Figlin, R. A. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1509 · Cited by 129
Enhancement of immune response to naked DNA vaccine by immunization with transfected dendritic cells
Manickan, E., Kanangat, S., Rouse, R., Yu, Z., & Rouse, B. T. (1997) · Journal of Leukocyte Biology · doi:10.1002/jlb.61.2.125 · Cited by 129
Tacken, P. J., Ginter, W., Berod, L., Cruz, L. J., Joosten, B., Sparwasser, T. D., Figdor, C. G., & Cambi, A. (2011) · Blood · doi:10.1182/blood-2011-04-346957 · Cited by 128
Kaplan-Lefko, P. J., Graves, J. D., Zoog, S. J., Pan, Y., Wall, J., Branstetter, D. G., Moriguchi, J., Coxon, A., Huard, J. N., Xu, R., et al. (2010) · Cancer Biology & Therapy · doi:10.4161/cbt.9.8.11264 · Cited by 126
Trial Watch: Immunostimulatory cytokines
Vacchelli, E., Galluzzi, L., Eggermont, A. M. M., Galon, J., Tartour, É., Zitvogel, L., & Kroemer, G. (2012) · OncoImmunology · doi:10.4161/onci.20459 · Cited by 122
Self-citationCanine parvovirus-like particles, a novel nanomaterial for tumor targeting
Singh, P. N. P., Destito, G., Schneemann, A., & Manchester, M. (2006) · Journal of Nanobiotechnology · doi:10.1186/1477-3155-4-2 · Cited by 120
Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy
Aranda, F., Vacchelli, E., Eggermont, A. M. M., Galon, J., Fridman, W. H., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2014) · OncoImmunology · doi:10.4161/onci.27297 · Cited by 119
Self-citationBrennan, T. V., Lin, L., Huang, X., Cardona, D. M., Li, Z., Dredge, K. S., Chao, N. J. A., & Yang, Y. (2012) · Blood · doi:10.1182/blood-2011-07-368720 · Cited by 118
Hoffman, L. M., & Gore, L. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00063 · Cited by 118
The immune landscape of human tumors: Implications for cancer immunotherapy
Bindea, G., Mlecnik, B., Angell, H. K., & Galon, J. (2014) · OncoImmunology · doi:10.4161/onci.27456 · Cited by 116
Self-citationBerraondo, P., Nouzé, C., Préville, X., Ladant, D., & Leclerc, C. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0321 · Cited by 113
Foloppe, J., Kintz, J., Futin, N., Findeli, A., Cordier, P., Schlesinger, Y., Hoffmann, C., Tosch, C., Balloul, J.-M., & Erbs, P. (2008) · Gene Therapy · doi:10.1038/gt.2008.82 · Cited by 110
Bridle, B. W., Chen, L., Lemay, C. G., Diallo, J., Pol, J. G., Nguyen, A., Capretta, A. A., He, R., Bramson, J. L., Bell, J. C., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2012.265 · Cited by 110
Phase I trial of liposomal muramyl tripeptide phosphatidylethanolamine in cancer patients.
Murray, J. L., Kleinerman, E. S., Cunningham, J. E., Tatom, J. R., Andrejcio, K., Lepe-Zuniga, J. L., LAMKI, L. M., Rosenblum, M. G., Frost, H., & Gutterman, J. U. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.12.1915 · Cited by 109
Trial Watch: Peptide vaccines in cancer therapy
Aranda, F., Vacchelli, E., Eggermont, A. M. M., Galon, J., Sautès‐Fridman, C., Tartour, É., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2013) · OncoImmunology · doi:10.4161/onci.26621 · Cited by 108
Self-citationTrial Watch: DNA vaccines for cancer therapy
Pol, J. G., Bloy, N., Obrist, F., Eggermont, A. M. M., Galon, J., Fridman, W. H., Cremer, I., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2014) · OncoImmunology · doi:10.4161/onci.28185 · Cited by 107
Self-citationCD73 promotes tumor growth and metastasis
Zhang, B. (2012) · OncoImmunology · doi:10.4161/onci.1.1.18068 · Cited by 106
Yamaguchi, H., Maruyama, T., Urade, Y., & Nagata, S. (2014) · eLife · doi:10.7554/elife.02172 · Cited by 106
Schildkopf, P., Frey, B., Ott, O. J., Rubner, Y., Multhoff, G., Sauer, R., Fietkau, R., & Gaipl, U. S. (2011) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2011.05.056 · Cited by 105
Rituximab: A New Therapeutic Monoclonal Antibody for Non‐Hodgkin's Lymphoma
Scott, S. D. (1998) · Cancer Practice · doi:10.1046/j.1523-5394.1998.006003195.x · Cited by 105
Liu, K., & Rosenberg, S. A. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.11.6356 · Cited by 105
Zeis, M., Siegel, S., Wagner, A., Schmitz, M., Marget, M., Kühl-Burmeister, R., Adamzik, I.-D., Kabelitz, D., Dreger, P., Schmitz, N., et al. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.11.5391 · Cited by 105
Zheng, X., Koropatnick, J. D., Chen, D., Velenosi, T. J., Ling, H., Zhang, X., Jiang, N., Navarro, B., Ichim, T. E., Urquhart, B. L., et al. (2012) · International Journal of Cancer · doi:10.1002/ijc.27710 · Cited by 105
Ma, Y., Adjemian, S., Yang, H., Catani, J. P. P., Hannani, D., Martins, I., Michaud, M., Kepp, O., Sukkurwala, A. Q., Vacchelli, E., et al. (2013) · OncoImmunology · doi:10.4161/onci.24568 · Cited by 104
Self-citationDeroose, J. P., Eggermont, A. M. M., van Geel, A. N., Burger, J. W. A., den Bakker, M. A., de Wilt, J. H. W., & Verhoef, C. K. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.6618 · Cited by 104
Self-citationEfficient Induction of Antitumor Immunity by Synthetic Toll-like Receptor Ligand–Peptide Conjugates
Zom, G. G., Khan, S., Britten, C. M., Sommandas, V., Camps, M. G. M., Loof, N. M., Budden, C. F., Meeuwenoord, N. J., Filippov, D. V., van der Marel, G. A., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0223 · Cited by 104
Self-citationTrial watch: Monoclonal antibodies in cancer therapy
Vacchelli, E., Eggermont, A. M. M., Galon, J., Sautès‐Fridman, C., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2012) · OncoImmunology · doi:10.4161/onci.22789 · Cited by 101
Self-citationGene Therapy: The First Approved Gene-Based Medicines, Molecular Mechanisms and Clinical Indications
Räty, J. K., Pikkarainen, J. T., Wirth, T. C., & Ylä‐Herttuala, S. (2008) · Current Molecular Pharmacology · doi:10.2174/1874467210801010013 · Cited by 99
Efficient nonviral transfection of dendritic cells and their use for in vivo immunization
Irvine, A. S., Trinder, P. K. E., Laughton, D. L., Ketteringham, H., McDermott, R. H., Reid, S. C. H., Haines, A. M. R., Amir, A., Husain, R. D., Doshi, R., et al. (2000) · Nature Biotechnology · doi:10.1038/82383 · Cited by 98
Blache, C. A., Manuel, E. R., Kaltcheva, T. I., Wong, A. N., Ellenhorn, J. D. I., Blazar, B. R., & Diamond, D. J. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0193 · Cited by 98
Immunological Effects of Bevacizumab-Based Treatment in Metastatic Colorectal Cancer
Manzoni, M., Rovati, B., Ronzoni, M., Loupakis, F., Mariucci, S., Ricci, V., Gattoni, E., Salvatore, L., Tinelli, C., Villa, E., et al. (2010) · Oncology · doi:10.1159/000320609 · Cited by 97
Conti, L., Lanzardo, S., Arigoni, M., Antonazzo, R., Radaelli, E., Cantarella, D., Calogero, R., & Cavallo, F. (2013) · The FASEB Journal · doi:10.1096/fj.13-230201 · Cited by 97
Self-citationTrial Watch: Anticancer radioimmunotherapy
Vacchelli, E., Vitale, I., Tartour, É., Eggermont, A. M. M., Sautès‐Fridman, C., Galon, J., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2013) · OncoImmunology · doi:10.4161/onci.25595 · Cited by 96
Self-citationHarmonization of Immune Biomarker Assays for Clinical Studies
van der Burg, S. H., Kalos, M. D., Gouttefangeas, C., Janetzki, S., Ottensmeier, C. H. H., Welters, M. J. P., Romero, P. J., Britten, C. M., & Hoos, A. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002785 · Cited by 95
Self-citationSmith, B. D., Kasamon, Y. L., Kowalski, J., Gocke, C. D., Murphy, K. M., Miller, C. B., Garrett-Mayer, E. S., Tsai, H., Lu, Q., Chia, C. Y., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2046 · Cited by 95
Pabst, T., Vellenga, E., van Putten, W., Schouten, H. C., Graux, C., Vekemans, M., Biemond, B. J., Sonneveld, P., Passweg, J. R., Verdonck, L. F., et al. (2012) · Blood · doi:10.1182/blood-2011-11-389841 · Cited by 95
Live-attenuated bacteria as a cancer vaccine vector
Toussaint, B., Chauchet, X., Wang, Y., Polack, B., & Gouëllec, A. L. (2013) · Expert Review of Vaccines · doi:10.1586/14760584.2013.836914 · Cited by 91
Forero, A., Infante, J. R., Waterhouse, D. M., Wong, L., Vickers, S. M., Arrowsmith, E. R., He, A. R., Hart, L. L., Trent, D. F., Wade, J. L., et al. (2013) · Cancer Medicine · doi:10.1002/cam4.137 · Cited by 90
Monoclonal antibodies: the story of a discovery that revolutionized science and medicine
Alkan, Ş. Ş. (2004) · Nature reviews. Immunology · doi:10.1038/nri1265 · Cited by 89
Creelan, B., Antonia, S. J., Bepler, G., Garrett, T. J., Simon, G. R., & Soliman, H. H. (2013) · OncoImmunology · doi:10.4161/onci.23428 · Cited by 86
Trial watch: DNA vaccines for cancer therapy
Senovilla, L., Vacchelli, E., Garcia, P., Eggermont, A. M. M., Fridman, W. H., Galon, J., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2013) · OncoImmunology · doi:10.4161/onci.23803 · Cited by 86
Self-citationNivolumab: A Review of Its Use in Patients with Malignant Melanoma
Deeks, E. D. (2014) · Drugs · doi:10.1007/s40265-014-0234-4 · Cited by 85
Trial Watch: Adoptive cell transfer immunotherapy
Galluzzi, L., Vacchelli, E., Eggermont, A. M. M., Fridman, W. H., Galon, J., Sautès‐Fridman, C., Tartour, É., Zitvogel, L., & Kroemer, G. (2012) · OncoImmunology · doi:10.4161/onci.19549 · Cited by 81
Self-citationCancer vaccines: Looking to the future
Yaddanapudi, K., Mitchell, R. A., & Eaton, J. W. (2013) · OncoImmunology · doi:10.4161/onci.23403 · Cited by 80
Trial Watch: Adoptive cell transfer for anticancer immunotherapy
Vacchelli, E., Eggermont, A. M. M., Fridman, W. H., Galon, J., Tartour, É., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2013) · OncoImmunology · doi:10.4161/onci.24238 · Cited by 79
Self-citationBuilding better magic bullets — improving unconjugated monoclonal antibody therapy for cancer
Weiner, L. M. (2007) · Nature reviews. Cancer · doi:10.1038/nrc2209 · Cited by 78
Spel, L., Boelens, J. J., Nierkens, S., & Boes, M. L. (2013) · OncoImmunology · doi:10.4161/onci.26403 · Cited by 77
LISTER, J. W., Rybka, W. B., Donnenberg, A. D., et al. (1995) · PubMed · Cited by 77
Antibody–drug conjugates: an emerging modality for the treatment of cancer
Leal, M., Sapra, P., Hurvitz, S. A., Senter, P. D., Wahl, A. F., Schutten, M. M., Shah, D. K., Haddish‐Berhane, N., & Kabbarah, O. (2014) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12499 · Cited by 76
Kauppila, J. H., Mattila, A. E., Karttunen, T. J., et al. (2013) · British Journal of Cancer · doi:10.1038/bjc.2012.589 · Cited by 76
Fallarino, F., Orabona, C., Vacca, C., Bianchi, R., Gizzi, S., Asselin‐Paturel, C., Fioretti, M. C., Trinchieri, G., Grohmann, U., & Puccetti, P. (2005) · International Immunology · doi:10.1093/intimm/dxh321 · Cited by 76
The machinery of Nod‐like receptors: refining the paths to immunity and cell death
Saleh, M. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2011.01045.x · Cited by 75
Deroose, J. P., Eggermont, A. M. M., van Geel, A. N., de Wilt, J. H. W., Burger, J. W. A., & Verhoef, C. K. (2011) · Annals of Surgical Oncology · doi:10.1245/s10434-011-2030-7 · Cited by 75
Self-citationLinks between Toll-like receptor 4 and breast cancer
Ahmed, A., Redmond, H. P., & Wang, J. H. (2013) · OncoImmunology · doi:10.4161/onci.22945 · Cited by 74
Subversion of the chemotherapy-induced anticancer immune response by the ecto-ATPase CD39
Michaud, M., Sukkurwala, A. Q., Martins, I., Shen, S., Zitvogel, L., & Kroemer, G. (2012) · OncoImmunology · doi:10.4161/onci.19070 · Cited by 74
Self-citationThe antitumor activity of TRAIL and IL-24 with replicating oncolytic adenovirus in colorectal cancer
Zhao, L., Dong, A., Gu, J., Liu, Z., Zhang, Y., Zhang, W., Wang, Y., He, L., Qian, C., Qian, Q., et al. (2006) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700969 · Cited by 73
Cheung, I. Y., Hsu, K. C., & Cheung, N. V. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.6236 · Cited by 72
DNA vaccines against cancer come of age
Stevenson, F. K., Ottensmeier, C. H. H., & Rice, J. (2010) · Current Opinion in Immunology · doi:10.1016/j.coi.2010.01.019 · Cited by 72
Kute, T., Stehle, J., Ornelles, D. A., Walker, N. K., Delbono, O., & Vaughn, J. P. (2012) · OncoImmunology · doi:10.4161/onci.20447 · Cited by 71
Potential of Transfected Muscle Cells to Contribute to DNA Vaccine Immunogenicity
Shirota, H., Petrenko, L., Hong, C., & Klinman, D. M. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.1.329 · Cited by 70
Clinical uses of GM-CSF, a critical appraisal and update
Arellano (2008) · Biologics · doi:10.2147/btt.s1355 · Cited by 70
Pegram, H. J., Jackson, J. T., Smyth, M. J., Kershaw, M. H., & Darcy, P. K. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.5.3449 · Cited by 70
Self-citationPD-L1 expression and tumor-infiltrating lymphocytes
Schalper, K. A. (2014) · OncoImmunology · doi:10.4161/onci.29288 · Cited by 67
Select forms of tumor cell apoptosis induce dendritic cell maturation
Demaria, S., Santori, F. R., Ng, B., Liebes, L., Formenti, S. C., & Vukmanović, S. (2004) · Journal of Leukocyte Biology · doi:10.1189/jlb.0804478 · Cited by 67
Gomes, E. M., Rodrigues, M. S., Phadke, A. P., Butcher, L. D., Starling, C. E., Chen, S., Chang, D., Hernández-Alcoceba, R., Newman, J. T., Stone, M. J., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1360 · Cited by 66
Li, J., O’Malley, M. E., Sampath, P., Kaliński, P., Bartlett, D. L., & Thorne, S. H. (2012) · Neoplasia · doi:10.1593/neo.121272 · Cited by 64
Baur, A. S., Lutz, M. B., Schierer, S., Beltrame, L., Theiner, G., Zinser, E., Ostalecki, C., Heidkamp, G. F., Haendle, I., Erdmann, M., et al. (2013) · Blood · doi:10.1182/blood-2012-09-456988 · Cited by 64
Sisirak, V., Faget, J., Vey, N., Blay, J., Ménétrier‐Caux, C., Caux, C., & Bendriss‐Vermare, N. (2012) · OncoImmunology · doi:10.4161/onci.22338 · Cited by 62
Self-citationSchmidt, T., Ziske, C. G., Märten, A., Endres, S., Tiemann, K., Schmitz, V., Gorschlüter, M., Schneider, C., Sauerbruch, T., & Schmidt‐Wolf, I. G. H. (2003) · PubMed · Cited by 61
Bridle, B. W., Clouthier, D., Zhang, L., Pol, J. G., Chen, L., Lichty, B. D., Bramson, J. L., & Wan, Y. (2013) · OncoImmunology · doi:10.4161/onci.26013 · Cited by 61
Spear, P., Barber, A., & Sentman, C. L. (2013) · OncoImmunology · doi:10.4161/onci.23564 · Cited by 61
High Expression of Ecto-Nucleotidases CD39 and CD73 in Human Endometrial Tumors
Aliagas, E., Vidal, A., Texidó, L., Ponce, J., Condom, E., & Martín-Satué, M. (2014) · Mediators of Inflammation · doi:10.1155/2014/509027 · Cited by 61
The immune checkpoint regulator PD-L1 is a specific target for naturally occurring CD4+T cells
Ahmad, S. M., Olofsson, G. H., Svane, I. M., & Andersen, M. H. (2013) · OncoImmunology · doi:10.4161/onci.23991 · Cited by 60
Curing Mice with Large Tumors by Locally Delivering Combinations of Immunomodulatory Antibodies
Dai, M., Yip, Y. Y., Hellström, I., & Hellström, K. E. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1339 · Cited by 60
Autophagy-assisted antigen cross-presentation
Yi, Y., Zhou, Z.-X., Shu, S., Fang, Y., Twitty, C., Hilton, T. L., Aung, S., Urba, W. J., Fox, B. A., Hu, H., et al. (2012) · OncoImmunology · doi:10.4161/onci.20059 · Cited by 59
Heat Shock Proteins (HSPs) Based Anti-Cancer Vaccines
Ciocca, D. R., Cayado-Gutiérrez, N., Maccioni, M., & Cuello-Carrión, F. D. (2012) · Current Molecular Medicine · doi:10.2174/156652412803306684 · Cited by 59
Withers, D. R., Gaspal, F., Bekiaris, V., McConnell, F. M., Kim, M., Anderson, G., & Lane, P. J. L. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2011.01057.x · Cited by 58
Therapeutic live vaccines as a potential anticancer strategy
Bolhassani, A., & Zahedifard, F. (2012) · International Journal of Cancer · doi:10.1002/ijc.27640 · Cited by 58
Dalrymple, S. L., Becker, R. E., & Isaacs, J. T. (2007) · The Prostate · doi:10.1002/pros.20573 · Cited by 58
Adoptive cell therapy: Honing that killer instinct
Humphries, C. A. (2013) · Nature · doi:10.1038/504s13a · Cited by 58
Salmonella as Live Trojan Horse for Vaccine Development and Cancer Gene Therapy
Moreno, M., Kramer, M. G., Yim, L., & Chabalgoity, J. A. (2010) · Current Gene Therapy · doi:10.2174/156652310790945566 · Cited by 58
Trial Watch: Immunostimulatory cytokines
Vacchelli, E., Eggermont, A. M. M., Fridman, W. H., Galon, J., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2013) · OncoImmunology · doi:10.4161/onci.24850 · Cited by 58
Self-citationCPG-7909 (PF-3512676, ProMune®): toll-like receptor-9 agonist in cancer therapy
Murad, Y. M., Clay, T. M., Lyerly, H. K., & Morse, M. A. (2007) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.7.8.1257 · Cited by 57
Satoh, Y., Esche, C., Gambotto, A. A., et al. (2002) · Journal of Experimental Therapeutics and Oncology · doi:10.1046/j.1359-4117.2002.01050.x · Cited by 57
Chemotherapy Induces Tumor Clearance Independent of Apoptosis
Guerriero, J. L., Ditsworth, D., Fan, Y., Zhao, F., Crawford, H. C., & Zong, W. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-2452 · Cited by 57
Trans-Presentation of IL-15 Dictates IFN-Producing Killer Dendritic Cells Effector Functions
Ullrich, E., Bonmort, M., Mignot, G., Jacobs, B., Bosisio, D., Sozzani, S., Jalil, A., Louache, F., Bulanova, E., Geissman, F., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.12.7887 · Cited by 55
Self-citationMignot, G., Ullrich, E., Bonmort, M., Menard, C., Apétoh, L., Taı̈eb, J., Bosisio, D., Sozzani, S., Ferrantini, M., Schmitz, J., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.10.6477 · Cited by 55
Self-citationAre oncoantigens suitable targets for anti-tumour therapy?
Cavallo, F., Calogero, R., & Forni, G. (2007) · Nature reviews. Cancer · doi:10.1038/nrc2208 · Cited by 55
Self-citationAllavena, P., Germano, G., Belgiovine, C., D’Incalci, M., & Mantovani, A. (2013) · OncoImmunology · doi:10.4161/onci.24614 · Cited by 55
The interplay between the immune system and chemotherapy: emerging methods for optimizing therapy
Ghiringhelli, F., & Apétoh, L. (2013) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2014.865520 · Cited by 55
Self-citationIdentification of a G-CSF-Granulocytic MDSC axis that promotes tumor progression
Abrams, S. I., & Waight, J. D. (2012) · OncoImmunology · doi:10.4161/onci.19334 · Cited by 54
Cited by
MYC regulates the antitumor immune response through CD47 and PD-L1
Casey, S. C., Tong, L., Li, Y., Do, R., Walz, S., Fitzgerald, K. N., Gouw, A. M., Baylot, V., Gütgemann, I., Eilers, M., et al. (2016) · Science · doi:10.1126/science.aac9935 · Cited by 1,403
Type I interferons in anticancer immunity
Zitvogel, L., Galluzzi, L., Kepp, O., Smyth, M. J., & Kroemer, G. (2015) · Nature Reviews Immunology · doi:10.1038/nri3845 · Cited by 1,305
Self-citationGuidelines for the use of flow cytometry and cell sorting in immunological studies (second edition)
Cossarizza, A., Chang, H., Radbruch, A., Acs, A., Adam, D., Adam‐Klages, S., Agace, W. W., Aghaeepour, N., Akdis, M., Allez, M., et al. (2019) · European Journal of Immunology · doi:10.1002/eji.201970107 · Cited by 979
Self-citationCurrent Challenges in Cancer Treatment
Zugazagoitia, J., Guedes, C., Ponce, S., Ferrer, I., Molina-Pinelo, S., & Paz-Ares, L. (2016) · Clinical Therapeutics · doi:10.1016/j.clinthera.2016.03.026 · Cited by 926
Immunity, inflammation, and cancer: an eternal fight between good and evil
Shalapour, S., & Karin, M. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80007 · Cited by 698
Metadata
- Authors
- Galluzzi, L., Vacchelli, E., Pedro, J.-M. B.-S., Buqué, A., Senovilla, L., Baracco, E. E., Bloy, N., Castoldi, F., Abastado, J.-P., Agostinis, P., Apte, R. N., Aranda, F., Ayyoub, M., Beckhove, P., Blay, J.-Y., Bracci, L., Caignard, A., Castelli, C., Cavallo, F., Celis, E., Cerundolo, V., Clayton, A., Colombo, M. P., Coussens, L., Dhodapkar, M. V., Eggermont, A. M., Fearon, D. T., Fridman, W. H., Fučíková, J., Gabrilovich, D. I., Galon, J., Garg, A., Ghiringhelli, F., Giaccone, G., Gilboa, E., Gnjatic, S., Hoos, A., Hosmalin, A., Jäger, D., Kalinski, P., Kärre, K., Kepp, O., Kiessling, R., Kirkwood, J. M., Klein, E., Knuth, A., Lewis, C. E., Liblau, R., Lotze, M. T., Lugli, E., Mach, J.-P., Mattei, F., Mavilio, D., Melero, I., Melief, C. J., Mittendorf, E. A., Moretta, L., Odunsi, A., Okada, H., Palucka, A. K., Peter, M. E., Pienta, K. J., Porgador, A., Prendergast, G. C., Rabinovich, G. A., Restifo, N. P., Rizvi, N., Sautès-Fridman, C., Schreiber, H., Seliger, B., Shiku, H., Silva-Santos, B., Smyth, M. J., Speiser, D. E., Spisek, R., Srivastava, P. K., Talmadge, J. E., Tartour, E., Van Der Burg, S. H., Van Den Eynde, B. J., Vile, R., Wagner, H., Weber, J. S., Whiteside, T. L., Wolchok, J. D., Zitvogel, L., Zou, W., & Kroemer, G.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2014-12-18
- Volume
- 5
- Issue
- 24
- Pages
- 12472-12508
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2134012905
- Cited by
- 468
- References
- 485
- FWCI
- 21.26
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.